Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Vendo a luz: intervenção precoce em pessoas em risco de transtorno bipolar

9 de novembro de 2026 atualizado por: Else Treffers, Geestelijke Gezondheidszorg Eindhoven (GGzE)

Um estudo exploratório e experimental para avaliar a viabilidade, aceitabilidade e eficácia da intervenção precoce com terapia de luz, estilo de vida e ImCT em indivíduos com risco de transtorno bipolar

In the current study, the feasibility, acceptability and effectivity of a new add-on early intervention program for individuals at risk for the development of bipolar disorder is evaluated. This intervention program entails psycho-education, light and lifestyle therapy in combination with Imagery focused Cognitive Therapy (ImCT). The program aims to contribute to early intervention by focusing on subclinical mood swings, anxiety symptoms, circadian rhythm and lifestyle factors such as activity level. We hypothesize a relationship between this early intervention and a significant improvement in mood symptoms, anxiety, subjective and objective sleep factors and lifestyle variables. Also, the feasibility, acceptability and associations with clinical improvement of symptoms will be studied.

Additionally, in a separate validation study, data will be collected to validate a new instrument for the early detection of those at risk for bipolar disorders. The Semistructured Interview of At Risk Bipolar States (SIBARS) (Fusar-Poli et al., 2022) will be translated and validated in a Dutch sample, in cooperation with its creators, Prof. Dr. P. Fusar-Poli and colleagues.

This intervention study is part of a larger research project in The Netherlands, GGzE Eindhoven. Researchers have started mapping the current use of psychological therapy, bright light therapy and lifestyle interventions in individuals presenting with mood symptoms that might be risk factors for future development of Bipolar Disorders. Based on the outcomes of this scoping review, a unique intervention program as described above will be formed.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Severe mental illnesses (SMI) distinguished as bipolar disorder and psychotic spectrum disorders, substantially impair patients' engagement in functional and occupational activities and severely limit social and societal functioning (GGZ Standaarden, 2022; NIH, 2022; NIMH, 2018). Based on the Dutch definition of SMI 1.7% of the national population suffers from an SMI (GGZ Standaarden, 2022). Despite this, time between first symptoms and accurate SMI diagnosis, can add up to more than 9.5 years in the case of bipolar disorders. For the psychotic spectrum, an early detection and intervention program (UHR) carried out by special EDI-Teams already exists, and has been found effective in limiting the transition to SMI with fifty percent. For bipolar disorders, no such program exists. This raises the question whether prodromal and subclinical symptoms of this disorder can be detected earlier and if transition into SMI can be limited. In light of current studies into the at-risk mental state, and the current development towards a possible transdiagnostic model for early detection and intervention of SMI (CHARMS-categories; (Liu et al., 2022)), the current study aims to contribute to limiting the transition into bipolar disorder. As a disturbance in circadian rhythm, as well as mood and anxiety symptoms are risk indicators for SMI in general and bipolar in specific, the current study evaluates an early intervention program for individuals at risk for developing an SMI, with a focus on bipolar symptomatology.

Individuals at risk will answer questions from the SIBARS interview. As explained in a publication of Fusar-Poli et al. (2022), "The Semi-structured Interview for Bipolar At Risk States (SIBARS) included a combination of several items adapted from well-established rating scales: (CAARMS (Yung et al., 2005); Hypomania Checklist-32 (Angst et al., 2005); Altman Self-Rating Mania Scale (Altman et al., 1997); TEMPS-A questionnaire (Akiskal et al., 2005); QIDS-SR (Rush et al., 2003); Bergen Insomnia Scale (Pallesen et al., 2008); Idiopathic hypersomnia questionnaire (Vernet et al., 2010)). The SIBARS interview was developed for youths aged 15-35 and comprehended 5 domains: 1. Subtreshold Mania, 2. Depression, 3. Cyclothymic Features, 4. Genetic Risk, 5. Mood Swings. Subtreshold Mania, Depression and Mood Swings are continuous rating scales (that include a severity and frequency anchors), while Cyclothyimc Features and Genetic Risk are categorical scales (yes/no). The cut-offs allow assigning the specific subgroup of the BARS criteria:

  1. Substreshold Mania
  2. Depression+Cyclothymic Features
  3. Depression+Genetic Risk
  4. Cyclothymic Features+Genetic Risk
  5. Subtreshold Mixed Episode
  6. Mood Swings."

Tipo de estudo

Intervencional

Inscrição (Estimado)

50

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • North Brabant
      • Eindhoven, North Brabant, Holanda, 5626ND
        • Recrutamento
        • Geestelijke Gezondheidszorg Eindhoven (GGzE)
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

16 anos a 35 anos (Filho, Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Must be bound to start the early intervention treatment being evaluated at GGzE
  • Aged 16-35, or > 35 by indication of the patients' treating clinician
  • Found to be at risk for SMI, as determined by the Early Detection and Intervention Team of GGzE
  • Sufficient knowledge of Dutch or English language
  • Ability to give informed consent
  • Willing to complete daily monitoring throughout the duration of the study

Exclusion Criteria:

  • Learningdifficulties,organicbraindiseaseorsevereneurologicalimpairment.
  • Previously received BLT (less than 3 weeks prior to study entry
  • Current severe substance or alcohol misuse (clinicians' assessment)
  • In case of BLT: eye problems contraindicating BLT and/or being unable to visit the GGzE

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Psycho-education and Imagery Focused Cognitive Therapy (in addition to Bright Light Therapy)

Treatment will be personalized in accordance to one of three options:

1. In case of depressive symptoms.

Bright Light Therapy (BLT) will be administered for 30 minutes on five consecutive days (duration: 1-3 weeks).

1 PE session focused on lifestyle and physical activity will take place. 6 sessions of ImCT will take place. This includes in-depth identification of images, constructing a micro-formulation along the lines of regular Cognitive Behavioural Therapy.

2. In case of hyperactivity symptoms.

The same PE and ImCT will be administered. The exception is that in this case, BLT is replaced by wearing blue-light blocking glasses for 1-3 weeks, 1 hour prior to bedtime.

3. In case of at risk mental state, but no clear depressive or hyperactive symptoms.

The same PE and ImCT will be administered. There will be no light intervention.

Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:

  • If the patient has achieved remission (QIDS-SR < 6), BLT has been successful and the patient can continue with PE and IMCT.
  • If there is insufficient or no response (QIDS-SR of 6 or higher), BLT is extended with five more sessions the following week.
  • If necessary, a third week is optional.

Week 2-4: Psycho Education will follow, 1 session.

Week 3/4-9/10: ImCT will follow, 6 sessions.

Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session.

Week 3/4-9/10: ImCT will follow, 6 sessions.

Week 1: Psycho Education, 1 session.

Week 2-7: ImCT will follow, 6 sessions.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in depressive symptom scores on the IDS-SR
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up

Significant lowering of IDS-SR questionnaire scores

at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
Change in hyperactive symptom scores on the ASRM
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up

Significant lowering of ASRM questionnaire scores

at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
Change in anxiety symptom scores on the BAI
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up

Significant lowering of BAI questionnaire scores

at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
Change in sleep quality subjective rating on 11-point Likert scale
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up

Significant improvement in subjective rating of sleep quality questionnaires

at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
Change in activity levels subjective rating on 11-point Likert scale
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up

Changes in daily and pre-post intervention self-report measurement of activity levels

at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Inge Bongers, Prof. Dr., GGzE, Tilburg University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de agosto de 2024

Conclusão Primária (Estimado)

9 de novembro de 2027

Conclusão do estudo (Estimado)

9 de novembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

3 de julho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de fevereiro de 2024

Primeira postagem (Real)

28 de fevereiro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • in progress

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The raw data is generated at the research location and is not shared with other researchers working elsewhere. After publication of the results, only data without privacy sensitive information and without study specific codes (fully anonymous), that support the findings are available from GGzE upon reasonable request (both in and outside the European Union). Before sharing this anonymous data, GGzE carefully investigates this request in consideration of the Dutch AVG and UAVG (Dutch Act on Implementation of the General Data Protection Regulation).

Prazo de Compartilhamento de IPD

After pilot, June 2025, protocol will be expanded to multi-centre level.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .